Sutro Biopharma Statistics
Total Valuation
Sutro Biopharma has a market cap or net worth of $145.95 million. The enterprise value is -$217.44 million.
Important Dates
The next estimated earnings date is Monday, March 24, 2025, after market close.
| Earnings Date | Mar 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Sutro Biopharma has 82.46 million shares outstanding. The number of shares has increased by 20.70% in one year.
| Current Share Class | 82.46M |
| Shares Outstanding | 82.46M |
| Shares Change (YoY) | +20.70% |
| Shares Change (QoQ) | +1.01% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 69.46% |
| Float | 74.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.79 |
| Forward PS | 3.62 |
| PB Ratio | 1.31 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.22.
| Current Ratio | 3.09 |
| Quick Ratio | 3.01 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.82 |
Financial Efficiency
Return on equity (ROE) is -110.89% and return on invested capital (ROIC) is -56.72%.
| Return on Equity (ROE) | -110.89% |
| Return on Assets (ROA) | -18.40% |
| Return on Invested Capital (ROIC) | -56.72% |
| Return on Capital Employed (ROCE) | -40.57% |
| Revenue Per Employee | $532,964 |
| Profits Per Employee | -$410,440 |
| Employee Count | 302 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sutro Biopharma has paid $15.82 million in taxes.
| Income Tax | 15.82M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.42% in the last 52 weeks. The beta is 1.15, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -62.42% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 3.29 |
| Relative Strength Index (RSI) | 42.90 |
| Average Volume (20 Days) | 950,687 |
Short Selling Information
The latest short interest is 4.07 million, so 4.94% of the outstanding shares have been sold short.
| Short Interest | 4.07M |
| Short Previous Month | 3.85M |
| Short % of Shares Out | 4.94% |
| Short % of Float | 5.48% |
| Short Ratio (days to cover) | 4.81 |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of $160.96 million and -$123.95 million in losses. Loss per share was -$1.73.
| Revenue | 160.96M |
| Gross Profit | -73.82M |
| Operating Income | -130.04M |
| Pretax Income | -97.16M |
| Net Income | -123.95M |
| EBITDA | -122.96M |
| EBIT | -130.04M |
| Loss Per Share | -$1.73 |
Full Income StatementBalance Sheet
The company has $388.25 million in cash and $24.86 million in debt, giving a net cash position of $363.39 million or $4.41 per share.
| Cash & Cash Equivalents | 388.25M |
| Total Debt | 24.86M |
| Net Cash | 363.39M |
| Net Cash Per Share | $4.41 |
| Equity (Book Value) | 111.22M |
| Book Value Per Share | 1.35 |
| Working Capital | 274.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$105.73 million and capital expenditures -$3.47 million, giving a free cash flow of -$109.20 million.
| Operating Cash Flow | -105.73M |
| Capital Expenditures | -3.47M |
| Free Cash Flow | -109.20M |
| FCF Per Share | -$1.32 |
Full Cash Flow StatementMargins
Gross margin is -45.86%, with operating and profit margins of -80.79% and -77.01%.
| Gross Margin | -45.86% |
| Operating Margin | -80.79% |
| Pretax Margin | -67.19% |
| Profit Margin | -77.01% |
| EBITDA Margin | -76.40% |
| EBIT Margin | -80.79% |
| FCF Margin | n/a |
Dividends & Yields
Sutro Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.70% |
| Shareholder Yield | -20.70% |
| Earnings Yield | -84.93% |
| FCF Yield | -74.82% |
Analyst Forecast
The average price target for Sutro Biopharma is $12.14, which is 585.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.14 |
| Price Target Difference | 585.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 15.90% |
| EPS Growth Forecast (5Y) | -3.79% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sutro Biopharma has an Altman Z-Score of -1.59 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.59 |
| Piotroski F-Score | 3 |